Carolyn Compton

SkySong, Suite 361
1475 North Scottsdale Road
Scottsdale
Professor
Faculty
TEMPE Campus
Mailcode
4501

Biography

Dr. Carolyn Compton is an academic pathologist specializing in gastrointestinal disease and is board certified in both anatomic and clinical pathology. She is a professor of Life Sciences at Arizona State University and a professor of laboratory medicine and pathology at the Mayo Clinic. She is also an adjunct professor of pathology at both the University of Arizona and Johns Hopkins University. She is the Chief Medical Officer of the National Biomarkers Development Alliance, a member of the Biodesign Institute at ASU, and the Chief Medical Officer of the Complex Adaptive Systems Institute. She is a former professor of pathology at Harvard Medical School, chief of Gastrointestinal Pathology at Massachusetts General Hospital and pathologist-in-chief of the Boston Shriners Children’s Hospital. More recently she has served as the CEO and president of the Critical Path Institute (2012), the director of Biorepositories and Biospecimen Research and the Innovative Molecular Analysis Technologies program at the National Cancer Institute (2005-2011), and the Strathcona Professor and chair of the Department of Pathology at McGill University and pathologist-in-chief of the McGill University Health Center (2000-2005). She is a past chair of the Cancer Committee of the College of American Pathologists and the immediate past chair of the American Joint Committee on Cancer (AJCC). Currently, she is the chair of the Precision Medicine Core of the AJCC and chair of the Pre-analytics for Precision Medicine Project Team at the College of American Pathologists. She has authored more than 500 scientific manuscripts, review articles, books and chapters.

Education

  • Ph.D..Harvard Graduate School of Arts & Sciences 1977
  • M.D. Harvard Medical School 1977
  • B.A. Bryn Mawr College 1969

Research Interests

colon cancer, medical prediction, cancer staging, biomarker development

Publications

  • GTEx Consortium. The genotype-Tissue Expression (GTEx) Project. NatGenetics 2013;45:580-5.
  • Goldman M, Compton C, Mittleman BB. Public-private Partnerships as Driving Forces in the Quest for Innovative Medicines. Clin Transl Med 2013;2:2.
  • Mucci NR, Moore HM, Brigham LE, Goldthwaite CA, Little AR, Lockhart NC, Scott MP, Struewing JP, Vincent Sl, Compton CC, for the cancer Human Biobank (caHUB). Acquisition of Normal Tissue Subgroup, National Cancer Institute Biopreservation and Biobanking. 2013 Apr;11:77-82.
  • Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DGB, McCormack R, Newcomer L, Pothier K, Ransohof D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a Vicious cycle. Science Transl Med 2013;5:1-7.
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg V, Donner DB, Mayer RJ, Goldberg RM, Compton C, Zuraek MB, Ye X, Saltz LB, Bertagnolli MM. Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. Clin Cancer Research 2013 Epub ahead of print.
  • Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK (eds). AJCC Staging Atlas. 2nd Edition. A Companion to the seventh Editions of the AJCC Staging Manual and Handbook.. New York, Springer, 2012.

*************************************************************************************************************************************************

  • 243. Webber C, Gospodarowicz M, Sobin LH, Greene FL, Masson MD, Compton C, Brierley J, Groome PA. Improving the TNM classification: Findings from a 10-year continuous literature review. Int J Cancer (2014).
  • 244. Barker AD, Compton CC, Poste G. The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic. Biomark Med (2014).
  • 245. David KA, Unger FT, Uhlig P, Juhl H, Moore HM, Compton C, Nashan B, Dörner A, de Weerth A, Zornig C. Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue. Oncotarget (2014).
  • Webber C, Gospodarowicz M, Sobin LH, Wittekind C, Greene FL, Mason MD, Compton C, Brierley J, and Groome PA. Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer (2014).
  • Goldman M, Compton C, Mittleman BB. Public-private Partnerships as Driving Forces in the Quest for Innovative Medicines. Clin Transl Med (2013).
  • Groelz D, Sobin L, Branton P, Compton C, Wyrich R, Rainen L. Non-formalin fixative versus formalin-fixed tissue: A comparison of histology and RNA quality. Exp Mol Pathol (2013).
  • GTEx Consortium. The genotype-Tissue Expression (GTEx) Project. Nat Genetics (2013).
  • Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DGB, McCormack R, Newcomer L, Pothier K, Ransohof D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a Vicious Cycle. Transl Med (2013).
  • Mucci NR, Moore HM, Brigham LE, Goldthwaite CA, Little AR, Lockhart NC, Scott MP, Struewing JP, Vincent Sl, Compton CC, for the cancer Human Biobank (caHUB). Acquisition of Normal Tissue Subgroup, National Cancer Institute. Biopreservation and Biobanking (2013).
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg V, Donner DB, Mayer RJ, Goldberg RM, Compton C, Zuraek MB, Ye X, Saltz LB, Bertagnolli MM. Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. Clin Cancer Research (2013).

Courses

Fall 2018
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
Spring 2018
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
BIO 493 Honors Thesis
BIO 591 Seminar
Fall 2017
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
Spring 2017
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
BIO 591 Seminar
Fall 2016
Course Number Course Title
BIO 189 Life Sciences Career Paths
BIO 302 Cancer-Mother of All Diseases
Summer 2016
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
BIO 494 Special Topics
Fall 2015
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
Spring 2015
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
Spring 2014
Course Number Course Title
BIO 302 Cancer-Mother of All Diseases
BIO 495 Undergraduate Research

Presentations

  • Compton CC. Biospecimens, Biomarkers and Genomics: Whats the Issue and Why Does It Matter?. NBDA Convergence Conference on Genomics (Dec 2014).
  • Compton CC. Biospecimens, Biomarkers and Proteomics: Whats the Issue and Why Does It Matter. NBDA Convergence Conference on Proteomics (Dec 2014).
  • Compton CC. Perspectives on Tissue Management Issues for Pathologist when Sending Tissue for Genomic Testing. College of American Pathologists Personalized healthcare Committee Meeting (Nov 2014).
  • Compton CC. Challenge, Convergence, Complexity and Change in Cancer Care: Are We Ready?. American College of Surgeons Annual Meeting (Oct 2014).
  • Compton CC. Biospecimens and Biomarkers: What Will It Take to Get to Precision Medicine?. World Congress on Skin Cancer (Sep 2014).
  • Compton CC. Biobanking and Precision Medicine for Cancer. Leaders in Biobanking Congress (Sep 2014).
  • Compton CC. The Right Stuff for Translational Biomedical Research: Garbage In, Garbage Out. Embracing Change: Enhancing Clinical Research Practices Conference (Sep 2014).
  • Compton CC. The Crisis in Biomarker Development for Cancer: What Will It Take to Get to Precision Medicine?. Annual Research Day, University of Dundee, Scotland (Sep 2014).
  • Compton CC. Leveraging Genomics In Oncology Clinical Development: Current And Future Benefits And Challenges. ASCO Annual Meeting (May 2014).
  • Compton CC. Technology Development, Disruptive Innovation and the Future of Oncology. American radium Society Annual Meeting (Apr 2014).
  • Compton CC. Accelerated FDA Approvals: What the Future Holds". CED Life Sciences Conference, Raleigh, SC (Feb 2014).

Service

  • Volitile Organic Compinds project of the Physical Sciences Oncology Centers program at the NCI, Scientific Advisor (2103 - Present)
  • Member Nominating Committee, American Joint Committee on CancerChair,, Chair (2013 - Present)
  • Feed My Starving Children, Faculty Sponsor (2013 - Present)
  • Precision Medicine Core Committee, American Joint Committee on Cancer, Chiar (2013 - Present)
  • American Joint Committee on Cancer, 8th Edition Cancer Staging Manual, Editorial Board (2012 - Present)
  • International Union for Cancer Control, TNM Committee, USA AJCC representative and member (2008 - Present)
  • Accreditation Committee, Commission on Cancer, American College of Surgeons, Member (2008 - Present)
  • Institute of Medicine, National Academy of Sciences, Expert Reviewer for IOM study: Management of The Air Force Health Study Data and Specimens - Report to Congress (2014 - 2014)
  • HealthTell, Board of Directors (2014 - 2014)
  • American Joint Committee on Cancer, Editorial Board of the 8th Edition of the Cancer Staging Manual (2014 - 2014)
  • American Joint Committee on Cancer, Executive Committee (2014 - 2014)
  • Commission on Cancer, American College of Surgeons, Executive Committee member (2014 - 2014)
  • Complex adaptive Systems Initiative, Chief Medical Officer (2014 - 2014)
  • Feed My Starving Children, Faculty Sponsor (2014 - 2014)
  • Indivumed GMBH, scientific consultant (2014 - 2014)
  • International Union for Cancer Control, USA representative to the TNM Staging Committee (2014 - 2014)
  • National Biomarker Development Alliance, Chief Medical Officer (2014 - 2014)
  • Precision Medicine Core of the American Joint Committee on Cancer, Chair (2014 - 2014)
  • Sun Devils for Public Health, Faculty Sponsor (2014 - 2014)
  • National Human Genome Research Institute, Expert Advisory Panel (2014 - 2014)
  • Summer Bridge Program, Lecturer/instrictor (2014 - 2014)
  • Clinical Data Interchange Standards Consortium, Board of Directors (2012 - 2013)
  • American Joint Committee on Cancer, Chairman (2008 - 2013)